Purdue Pharma Opioid Settlement: What Victims Actually Get

Two enormous numbers get repeated constantly in coverage of opioid litigation — $50 billion, then $7.4 billion — and neither one tells an individual victim what they’ll actually receive. The honest answer involves a Supreme Court ruling that blew up the original plan, a documentation requirement that has already disqualified tens of thousands of people, and a fund that, as of this writing, still hasn’t paid out.

Quick answer: A roughly $50 billion national settlement with opioid distributors and manufacturers pays states and local governments, not individual victims directly. Separately, Purdue Pharma’s own bankruptcy created the only fund built specifically for individual claimants — but the Supreme Court, in Harrington v. Purdue Pharma L.P. (2024), struck down the original plan’s release of the Sackler family, forcing a renegotiation. The revised plan, effective May 1, 2026, set aside up to $865 million for individual victims through the Purdue Personal Injury Trust — but a strict documentation requirement has already led to roughly 80,000 claimants being formally removed and more than 40% of claims rejected, and as of this writing, payments to qualified claimants had not yet begun.

Two Completely Separate Pools of Money

The most consequential thing to understand about opioid litigation is that it produced two entirely separate settlement tracks, and only one of them was ever built to pay individuals directly.

• The national distributor and manufacturer settlement — resolving claims brought mostly by states and local governments against companies including McKesson, Cardinal Health and AmerisourceBergen (up to $21 billion over 18 years from the distributors alone), plus additional settlements with manufacturers and pharmacy chains that brought the combined national total past $50 billion. The underlying federal case, National Prescription Opiate Litigation, is centralized as an MDL in the Northern District of Ohio — see our explainer on how mass tort litigation actually works for what that structure generally means. Under the settlement’s own allocation formula, states and their subdivisions are the only eligible recipients — the money funds abatement programs like addiction treatment and prevention infrastructure, not payments to the people who were personally harmed.
• Purdue Pharma’s own, separate Chapter 11 bankruptcy — filed in 2019, specifically because Purdue itself, unlike most of the distributor and manufacturer defendants, faced potential liability large enough to threaten its survival. This bankruptcy is the only track that created a dedicated fund for individual personal injury and wrongful death victims — but getting there required surviving a fight that went all the way to the Supreme Court.

Harrington v. Purdue Pharma: Why the Original Deal Collapsed

Purdue’s original 2021 bankruptcy plan offered a specific trade: members of the Sackler family, who controlled and profited enormously from Purdue without ever filing for bankruptcy themselves, would contribute about $4.3 billion to the bankruptcy estate. In exchange, the plan released the Sacklers from all current and future civil opioid claims — including claims by individual victims who never agreed to give them up.

In Harrington v. Purdue Pharma L.P., 603 U.S. 204 (2024), decided June 27, 2024 by a 5-4 vote, the Supreme Court rejected that structure. Justice Gorsuch, writing for the majority (joined by Justices Thomas, Alito, Barrett and Jackson), held that the Bankruptcy Code does not authorize a plan provision releasing claims against a non-debtor without the consent of the affected claimants — the Sacklers were never bankrupt themselves, and a bankruptcy court’s power to discharge debts extends to the debtor before it, not to third parties who simply pay into the settlement. Justice Kavanaugh dissented, joined by Chief Justice Roberts and Justices Sotomayor and Kagan, warning the ruling would unravel a deal years in the making and jeopardize compensation for victims who had already voted to approve it.

The ruling didn’t end the case. It sent Purdue back to renegotiate a plan that could actually survive — one where victims consented, individually, to whatever release of Sackler liability the plan required.

The Revised Plan: Opt-In, Not Automatic

The plan that emerged uses a structure built directly around Harrington’s holding. Claimants faced a real choice, not a forced release:

• Accept the Sackler release and receive a distribution from both the Purdue bankruptcy estate and a new, additional “direct claims” settlement pool the Sacklers funded specifically to secure that consent, or
• Decline the release, preserve the right to pursue the Sacklers individually in a separate lawsuit, and receive only the smaller share available from the bankruptcy estate itself.

The deadline to make that choice was March 1, 2026. The bankruptcy court confirmed the revised plan on November 18, 2025, with a total value of roughly $7.4 billion — a larger contribution from the Sackler family than the plan the Supreme Court had rejected — and the plan became legally effective on May 1, 2026.

The Individual Victim Fund — and Its Documentation Problem

Of that $7.4 billion, up to $865 million was set aside specifically for the Purdue Personal Injury Trust, covering individual personal injury and wrongful death claims — including a separate category for claims involving neonatal abstinence syndrome (NAS), where a child was born opioid-dependent. Approximately $815 million was actually funded to the trust on the plan’s May 1, 2026 effective date.

Reaching that money has proven far harder than filing the original claim. The original bar date to file a proof of claim in Purdue’s bankruptcy was September 21, 2021 — a deadline that has been closed for years, and one this guide cannot help anyone reopen. But even for people who filed on time, the revised plan eliminated an earlier option that would have let a claimant without documentation qualify for a smaller, flat payment by signing a sworn affidavit attesting to their opioid use. In its place, the trust required actual prescription, medical or legal records — frequently reaching back a decade or more, well past the period many pharmacies, physicians and insurers are required to retain such records at all.

The consequences have been severe. In April 2026, a federal judge approved a motion formally removing roughly 80,000 claimants who had missed the resulting documentation deadline, and by that point more than 40% of submitted claims had reportedly already been rejected. As of this guide’s publish date, the trust had not yet begun disbursing payments to the claimants who did qualify, though its administrator has indicated payments could begin around the middle of 2026 — a timeline that, like much of this process, has already shifted more than once.

If You Never Filed, or Your Claim Was Rejected

If you were personally harmed by a Purdue opioid product and never filed a claim by the September 21, 2021 bar date, this specific trust is very likely closed to you — there is no indication a new filing window exists or is planned. That is a genuinely hard outcome to hear, but it does not necessarily mean every avenue is closed:

• Claims against other manufacturers, distributors or pharmacy chains that were not part of Purdue’s bankruptcy remain a separate, ordinary product liability question, on whatever timeline your state’s statute of limitations allows.
• A claim against a specific prescriber or pharmacy for negligent prescribing or dispensing runs on an entirely different, ordinary medical malpractice or pharmacy-malpractice theory — see our guide to medication errors and pharmacy malpractice claims for how that framework works.
• If your claim was rejected for a documentation reason, confirming whether an appeal or reconsideration process exists within the trust’s own procedures, rather than assuming a rejection is automatically final, is worth doing immediately with an attorney.

Evidence That Actually Matters

• Pharmacy fill records identifying the specific opioid product, dosage and dates
• Physician prescription records, including the prescribing provider’s name and practice
• Insurance claim records showing the specific medication billed
• Medical records connecting a diagnosis — including NAS in a child — directly to opioid use
• Any prior correspondence with the Purdue Personal Injury Trust confirming what has already been submitted and what, if anything, remains outstanding

Practical Steps

1. If you already filed a claim, confirm its current status directly with the Purdue Personal Injury Trust rather than assuming no news is good news.
2. Locate and submit any prescription, medical or insurance documentation immediately if your claim’s evidence deadline hasn’t fully closed, since retention windows at pharmacies and providers only get worse with time.
3. Ask providers and pharmacies directly for older records, rather than assuming they no longer exist — some retain records longer than the statutory minimum.
4. If you never filed by the original 2021 deadline, don’t assume you have no remaining claim at all — a separate manufacturer, distributor, pharmacy or prescriber may still be a viable, ordinary defendant outside Purdue’s bankruptcy.
5. Don’t confuse the $50 billion state and local settlement with a source of individual compensation — it isn’t one, and no amount of following that litigation’s news will change your own claim’s status.
6. Consult an attorney experienced in opioid litigation and mass-tort bankruptcy claims specifically, given how unusual and fast-changing this process has been.

Sources & Further Reading

• Harrington v. Purdue Pharma L.P., 603 U.S. 204 (2024), decided June 27, 2024 — holding that the Bankruptcy Code does not authorize a non-consensual release of claims against a non-debtor third party
• Purdue Pharma bankruptcy docket, U.S. Bankruptcy Court, Southern District of New York — the revised, confirmed Chapter 11 plan (confirmed November 18, 2025, effective May 1, 2026) and Purdue Personal Injury Trust claims administration records
• National Prescription Opiate Litigation, MDL No. 2804 (N.D. Ohio) — the separate federal multidistrict litigation underlying the roughly $50 billion national distributor and manufacturer settlement
• Reporting on the Purdue Personal Injury Trust’s 2025-2026 documentation requirements, the resulting claimant expungement approved in April 2026, and the trust’s payment timeline
• See our guides to how mass tort litigation actually works for the MDL structure behind the government settlement and how a bankruptcy channeling injunction compares to it, filing a claim in a class action or mass tort settlement for what to do if your own claim is flagged as deficient, medication errors and pharmacy malpractice claims for the separate, ordinary claim against a specific prescriber or pharmacy, and the 3M Combat Arms earplug litigation for another company whose subsidiary bankruptcy filing, attempting the same kind of non-debtor liability shield, was also rejected by a federal judge